Filtering





OP33: Oral ritlecitinib and brepocitinib in patients with Moderate to Severe Active Ulcerative Colitis: Data from the VIBRATO umbrella studyECCO'21 Virtual
Year: 2021
Authors: Sandborn, W.(1);Danese, S.(2);Leszczyszyn, J.(3);Romatowski, J.(4);Altintas, E.(5);Peeva, E.(6);Vincent, M.(6);Reddy, P.(7);Banfield, C.(7);Banerjee, A.(7);Gale, J.(6);Hung, K.(6)
(1)University of California San Diego, Gastroenterology, La Jolla, United States;(2)Humanitas Research Hospital, Gastroenterology, Milan, Italy;(3)Melita Medical, Gastroenterology, Wroclaw, Poland;(4)Provincial Complex Hospital, Gastroenterology, Bialystok, Poland;(5)Mersin University, Gastroenterology, Mersin, Turkey;(6)Pfizer Inc., Inflammation and Immunology, Cambridge, United States;(7)Pfizer Inc., Early Clinical Development, Cambridge, United States
OP34: AJM300, an Oral Antagonist of α4-Integrin, as induction therapy for patients with Moderately Active Ulcerative Colitis: A Phase 3, randomized, double-blind, placebo-controlled induction studyECCO'21 Virtual
Year: 2021
Authors: Watanabe, M.(1);Matsuoka, K.(2); Ohmori, T.(3);Nakajima, K.(4);Ishida, T.(5);Ishiguro , Y.(6);Kanke, K.(7);Kobayashi, K.(8);Hirai, F.(9);Watanabe, K.(10);Hibi, T.(11)
(1)Tokyo Medical and Dental University, Advanced Research Institute, Tokyo, Japan;(2)Toho University Sakura Medical Center, Department of Gastroenterology and Hematology, Chiba, Japan;(3)Ohmori Toshihide gastro-intestinal Clinic, Gastroenterology, Saitama, Japan;(4)Matsushima Clinic Yokohama Japan, Department of gastrointestinal division, Kanagawa, Japan;(5)Ishida Clinic of IBD and Gastroenterology, IBD and Gastroenterology, Oita, Japan;(6)National Hospital Organization Hirosaki National Hospital, Department of Gastroenterology and Hematology, Aomori, Japan;(7)Kanke Gastrointestinal Clinic, Gastrointestinal division, Tochigi, Japan;(8)Kitasato University School of Medicine, Research and Development Center for New Medical Frontiers, Kanagawa, Japan;(9)Fukuoka University Hospital, Department of Gastroenterology and Medicine, Fukuoka, Japan;(10)Hyogo College Of Medicine College Hospital, Department of Intestinal Inflammation Research, Hyogo, Japan;(11)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan
OP35: Effect of maintenance ustekinumab on corticosteroid-free endoscopic and clinical outcomes in patients with Crohn's Disease - Week 48 analysis of the STARDUST trialECCO'21 Virtual
Year: 2021
Authors: Danese, S.(1);Vermeire, S.(2);D’Haens, G.(3);Panés, J.(4);Dignass, A.(5);Magro, F.(6,7);Nazar, M.(8);Le Bars, M.(9);Lahaye, M.(10);Ni, L.(11);Bravatà, I.(12);Gaya, D.R.(13);Peyrin-Biroulet, L.(14)
(1)Humanitas University, IBD Center, Milan, Italy;(2)University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium;(3)University of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands;(4)Hospital Clinic of Barcelona- IDIBAPS- CIBERehd, Department of Gastroenterology, Barcelona, Spain;(5)Agaplesion Markus Hospital, Department of Medicine I, Frankfurt/Main, Germany;(6)Institute for Molecular and Cell Biology- Faculty of Medicine University of Porto, Department of Pharmacology & Therapeutics, Porto, Portugal;(7)Hospital de São João, Department of Gastroenterology, Porto, Portugal;(8)Janssen-Cilag Polska Sp. z .o.o., Medical Affairs, Warsaw, Poland;(9)Janssen-Cilag, Medical Affairs, Issy-les-Moulineaux, France;(10)Janssen-Cilag BV, Medical Affairs, Breda, The Netherlands;(11)Janssen Cilag Russia, Medical Affairs, Moscow, Russian Federation;(12)Janssen-Cilag, Medical Affairs, Milan, Italy;(13)Glasgow Royal Infirmary, Department of Gastroenterology, Glasgow, United Kingdom;(14)University Hospital of Nancy- University of Lorraine, INSERM Unité 954 and Department of Hepato-Gastroenterology, Houdemont, France
OP36: Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studiesECCO'21 Virtual
Year: 2021
Authors: Bossuyt, P.(1);Ferrante, M.(2);Baert, F.(3);Danese, S.(4);Feagan, B.G.(5);Loftus Jr, E.V.(6);Panés, J.(7);Peyrin-Biroulet, L.(8);Ran, Z.(9);Armuzzi, A.(10);D’Haens, G.R.(11);SONG, A.(12);Neimark, E.(12);Liao, X.(12);Zhou, Q.(12);Berg, S.(12);Wallace, K.(12);Panaccione, R.(13)
(1)Imelda General Hospital, Bonheiden, Belgium;(2)University Hospitals Leuven, Leuven, Belgium;(3)AZ Delta, Roeselare-Menen, Belgium;(4)Istituto Clinico Humanitas, Milan, Italy;(5)Western University, London, Canada;(6)Mayo Clinic, Rochester, United States;(7)Hospital Clinic Barcelona, Barcelona, Spain;(8)University Hospital of Nancy and Lorraine University, Vandoeuvre, France;(9)Shanghai Jiao Tong University, Shanghai, China;(10)Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy;(11)Amsterdam University Medical Centers, Amsterdam, The Netherlands;(12)AbbVie Inc, North Chicago, United States;(13)University of Calgary, Calgary, Canada
OP37: Rapidity of symptom improvements during filgotinib induction therapy in patients with Ulcerative Colitis: Post hoc analysis of the phase 2b/3 SELECTION studyECCO'21 Virtual
Year: 2021
Authors: Danese, S.(1);Hibi, T.(2);Ritter, T.E.(3);Dinoso, J.B.(4);Hsieh, J.(4);Yun, C.(4);Zhang, J.(4);Zhao, S.(4);Loftus Jr, E.V.(5);Rogler, G.(6)
(1)Humanitas Clinical and Research Center- IRCCS and Humanitas University, Department of Gastroenterology, Milan, Italy;(2)Kitasato Institute Hospital- Kitasato University, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(3)GI Alliance, Department of Research and Education, Southlake- TX, United States;(4)Gilead Sciences, Inc., Foster City, United States;(5)Mayo Clinic, Department of Internal Medicine- Division of Gastroenterology and Hepatology, Rochester- MN, United States;(6)University Hospital of Zurich- University of Zurich, Clinic for Gastroenterology and Hepatology, Zurich, Switzerland
OP38: Developing a Cost-Effective Genomic Biomarker of Cancer Risk in Patients with Ulcerative Colitis using Low-Pass Whole Genome Sequencing of Unselected Endoscopic Biopsies: A Case-Control StudyECCO'21 Virtual
Year: 2021
Authors: Al Bakir, I.(1);Curtius, K.(1);Smith, K.(1);Kopczynska, M.(1);Moorghen, M.(2);Hart, A.(3);Graham, T.(1)
(1)Queen Mary University of London, Barts Cancer Institute, London, United Kingdom;(2)St. Mark's Hospital, Pathology Department, Harrow, United Kingdom;(3)St. Mark's Hospital, Gastroenterology Department, Harrow, United Kingdom
OP39: The effect of phenotype and genotype on the plasma proteome in patients with Inflammatory Bowel DiseaseECCO'21 Virtual
Year: 2021
Authors: Bourgonje, A.R.(1);Hu, S.(1);Spekhorst, L.M.(1);Zhernakova, D.V.(2);Vich Vila, A.(1);Li, Y.(1);Voskuil, M.D.(1);van Berkel, L.A.(3);Bley Folly, B.(3);Charrout, M.(4);Mahfouz, A.(4);Reinders, M.J.T.(4);van Heck, J.I.P.(5);Joosten, L.A.B.(5);Visschedijk, M.C.(1);van Dullemen, H.M.(1);Faber, K.N.(1);Samsom, J.N.(3);Festen, E.A.M.(1);Dijkstra, G.(1);Weersma, R.K.(1)
(1)University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands;(2)University Medical Center Groningen, Genetics, Groningen, The Netherlands;(3)Erasmus University Medical Center, Pediatrics- Division of Gastroenterology, Rotterdam, The Netherlands;(4)Delft University of Technology and Leiden University Medical Center, Delft Bioinformatics Lab and Leiden Computational Biology Center, Delft- Leiden, The Netherlands;(5)Radboud University Medical Center, Internal Medicine and Institute of Molecular Life Sciences, Nijmegen, The Netherlands
OP40: Analysis of clinical features associated with favourable outcomes from ustekinumab treat-to-target strategy in Crohn’s Disease patients in the STARDUST trialECCO'21 Virtual
Year: 2021
Authors: Danese, S.(1);Vermeire, S.(2);Dignass, A.(3);Panés, J.(4);D'Haens, G.(5);Magro, F.(6,7);Le Bars, M.(8);Nazar, M.(9);Lahaye, M.(10);Ni, L.(11);Bravatà, I.(12);Gaya, D.R.(13);Peyrin-Biroulet, L.(14)
(1)Humanitas University, IBD Center, Milan, Italy;(2)University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium;(3)Agaplesion Markus Hospital, Department of Medicine I, Frankfurt/Main, Germany;(4)Hospital Clinic of Barcelona- IDIBAPS- CIBERehd, Department of Gastroenterology, Barcelona, Spain;(5)University of Amsterdam, Amsterdam Medical Center, Amsterdam, The Netherlands;(6)Institute for Molecular and Cell Biology- Faculty of Medicine University of Porto, Department of Pharmacology & Therapeutics, Porto, Portugal;(7)Hospital de São João, Department of Gastroenterology, Porto, Portugal;(8)Janssen-Cilag, Medical Affairs, Issy-les-Moulineaux, France;(9)Janssen-Cilag Polska Sp. z .o.o., Medical Affairs, Warsaw, Poland;(10)Janssen-Cilag BV, Medical Affairs, Breda, The Netherlands;(11)Janssen Cilag Russia, Medical Affairs, Moscow, Russian Federation;(12)Janssen-Cilag, Medical Affairs, Milan, Italy;(13)Glasgow Royal Infirmary, Department of Gastroenterology, Glasgow, United Kingdom;(14)University Hospital of Nancy- University of Lorraine, INSERM Unité 954 and Department of Hepato-Gastroenterology, Houdemont, France
P001: Succinate, a gut microbiota-derived metabolite, modulates the inflammatory status of the creeping fat in Crohn’s disease.ECCO'21 Virtual
Year: 2021
Authors: Serena, C.(1);Monfort-Ferre, D.(1);Bautista, M.(2);Menacho, M.(2);Martí, M.(3);Espin, E.(3);Vendrell, J.(1);Fernández-Veledo, S.(1);
(1)Health Institute Pere Virgili IISPV, Hospital Universitari Joan XXIII of Tarragona, Tarragona, Spain;(2)Hospital Universitari Joan XXIII of Tarragona, Digestive Service, Tarragona, Spain;(3)Hospital Universitari Vall Hebron, Surgery Service, Barcelona, Spain
P002: Methodological development of single-cell phenotyping and spatial analysis of intestinal leukocyte, stromal and epithelial cell populations in inflammatory bowel disease formalin fixed paraffin embedded tissue by Hyperion imaging mass cytometryECCO'21 Virtual
Year: 2021
Authors: Lamb, C.A.(1,2);Doyle, J.(1);Hulme, G.(3);Cooke, K.(1);Au-Yeung, A.(4);Ojeda-Garcia, J.(3);Fuller, A.(3);McDonald, D.(3);Mansfield, J.C.(1,2);Kirby, J.A.(1);McBride, J.(4);Speight, R.A.(1,2);O’Gorman, W.(4);Filby, A.(3);
(1)Newcastle University, Translational and Clinical Research Institute, Newcastle upon Tyne, United Kingdom;(2)Newcastle upon Tyne Hospitals NHS Foundation Trust, Department of Gastroenterology, Newcastle upon Tyne, United Kingdom;(3)Newcastle University, Flow Cytometry Core Facility and Innovation- Methodology and Application Research Theme- Biosciences Institute- Faculty of Medical Sciences, Newcastle upon Tyne, United Kingdom;(4)Genentech Inc, Department of OMNI Biomarker Development, South San Francisco, United States
P003: HDAC7 Controls Differentiation and Regeneration in the Intestinal EpitheliumECCO'21 Virtual
Year: 2021
Authors: Gerbeth, L.(1);Glauben, R.(1);Siegmund, B.(1);
(1)Charité - Universitätsmedizin Berlin, Medical Department of Gastroenterology- Infectiology and Rheumatology, Berlin, Germany
P004: Critical paralog proteins has a cell-type specific rewiring role in Ulcerative Colitis associated signalling processesECCO'21 Virtual
Year: 2021
Authors: Kornilova, P.(1);Potari-Gul, L.(1);Modos, D.(1,2);Madgwick, M.(1,2);Haerty, W.(1);Korcsmaros, T.(1,2);
(1)Earlham Institute- Norwich Research Park, Organisms and Ecosystems, Norwich, United Kingdom;(2)Quadram Institute Bioscience- Norwich Research Park, Gut Microbes and Health Programme, Norwich, United Kingdom
P005: Cytokine mediated intercellular communication in inflammatory bowel diseaseECCO'21 Virtual
Year: 2021
Authors: Thomas, J.P.(1,2,3);Olbei, M.(2,3);Hautefort, I.(2);Modos, D.(2,3);Korcsmaros, T.(2,3);
(1)Norfolk and Norwich University Hospitals-, Department of Gastroenterology, Norwich, United Kingdom;(2)Quadram Institute Bioscience, Gut Microbes and Health Programme, Cambridge, United Kingdom;(3)Earlham Institute, Earlham Institute, Norwich, United Kingdom
P006: Host-genetics, dysbiosis, and clinical history explains fecal metabolic alterations in patients with Inflammatory Bowel DiseaseECCO'21 Virtual
Year: 2021
Authors: Vich Vila, A.(1);Hu, S.(1);Andreu-Sánchez, S.(2);Collij, V.(1);Jansen, D.(1);Ruigrok, R.(1);Abu-Ali, G.(3);Parkinson, J.(3);Al Garawi, A.(3);Schneider, J.(3);Kurilshikov, A.(2);Björk, J.(1);Gacesa, R.(1);Fu, J.(2);Zhernakova, A.(2);Weersma, R.K.(1);
(1)University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands;(2)University Medical Center Groningen, Genetics, Groningen, The Netherlands;(3)Takeda Pharmaceutical Company Limited, Gastroenterology Drug Discovery Unit, Cambridge, United States
P007: Identification and characterisation of intestine-derived circulating resident memory T cells (ex-Trm) in health and Inflammatory Bowel DiseaseECCO'21 Virtual
Year: 2021
Authors: Rodger, B.(1);Hoti, I.(1);Gordon, H.(1);Lindsay, J.(1);Stagg, A.(1);
(1)Blizard Institute- Queen Mary University of London, Centre for Immunobiology, London, United Kingdom
P008: Store-operated calcium entry controls immune cell function and activation in Inflammatory Bowel DiseaseECCO'21 Virtual
Year: 2021
Authors: Letizia, M.(1);Kaufmann, U.(2);Gerbeth, L.(1);Sand, A.(1);Brunkhorst, M.(1);Wang, Y.(2);Böttcher, C.(3);Schlickeiser, S.(4);Fernández-Zapata, M.C.(3);Kunkel, D.(4);Siegmund, B.(1);Feske, S.(2);Weidinger, C.(1);
(1)Charité Universitätsmedizin Berlin, Medical Department- Division of Gastroenterology- Infectiology and Rheumatology, Berlin, Germany;(2)New York University, Department of Pathology, New York, United States;(3)Charité Universitätsmedizin Berlin, Laboratory of Molecular Psychiatry- Charité, Berlin, Germany;(4)Charité Universitätsmedizin Berlin, Berlin-Brandenburger Centrum für Regenerative Therapien, Berlin, Germany IBDome researchers
P009: Disease classifier and microbial dysbiosis index tools cross-predict various pathogenic conditions due to general microbial signalECCO'21 Virtual
Year: 2021
Authors: Abbas Egbariya, H.(1);Braun, T.(2);Hadar , R.(2);Gal-Mor, O.(1);Shental, N.(3);Haberman, Y.(4);Amir, A.(2);
(1)Tel Aviv university - Faculty of Medicine, microbiology, Tel Aviv, Israel;(2)Sheba medical center, microbiome center, Ramat Gan, Israel;(3)The Open University of Israel, Department of Mathematics and Computer Science, Ra’anana, Israel;(4)Sheba medical center, pediatric gastroenterology, Ramat Gan, Israel
P010: GSDMB-mediated pyroptosis exacerbates intestinal inflammation by destroying intestinal epithelium in Crohn’s diseaseECCO'21 Virtual
Year: 2021
Authors: Gong, W.(1);Liu, P.(2);Ren, J.(3);
(1)Southeast University, School of Medicine, Nanjing, China;(2)Nanjing University, School of Medicine, Nanjing, China;(3)Jinling Hospital, General Surgerry, Nanjing, China
P011: Serum adhesion G protein coupled receptor levels are associated with disease activity in pediatric patients with Crohn’s diseaseECCO'21 Virtual
Year: 2021
Authors: Werner, L.(1);Weiss, B.(2);Shamir, R.(1);Shouval, D.(1);
(1)Schneider Children's Medical Center of Israel, Institute of Gastroenterology- Nutrition and Liver Diseases, Petah Tiqwa, Israel;(2)Edmond and Lily Safra Children's Hospital- Sheba Medical Center, Pediatric Gastroenterology, Ramat Gan, Israel
P012: Low frequencies of circulating inhibitory TIGIT+CD38+ effector T cells identify an immunologically distinct subgroup of pediatric patients with severe Crohn's diseaseECCO'21 Virtual
Year: 2021
Authors: Heredia, M.(1);Costes, L.(1);Tindemans, I.(1);Aardoom, M.(2);Klomberg, R.(2);Kemos, P.(3);Joosse, M..(1);van Haaften, D.(1);Tuk, B.(1);Ruemmele, F.(4);Croft, N.(3);Escher, J.(2);de Ridder, L.(2);Samsom, J.(1);
(1)Erasmus University Medical Center-Sophia Children’s Hospital, Laboratory of Pediatrics- division Gastroenterology and Nutrition, Rotterdam, The Netherlands;(2)Erasmus University Medical Center-Sophia Children’s Hospital, Pediatric Gastroenterology, Rotterdam, The Netherlands;(3)Blizard Institute- Queen Mary University of London, Centre for Immunobiology, London, United Kingdom;(4)Necker-Enfants Malades University Hospital- Institut Imagine- AP-HP- Université de Paris, Pediatric Gastroenterology, Paris, France